Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Quiescin sulfhydryl oxidase 1 (QSOX1) is a flavin-linked enzyme that catalyzes the de novo formation of disulfide bonds in proteins, primarily within the Golgi apparatus and the extracellular space [UniProt, MDPI]. Unlike the classical protein disulfide isomerases found in the endoplasmic reticulum, QSOX1 directly reduces molecular oxygen to hydrogen peroxide while oxidizing thiol groups in substrate proteins to disulfides [NCBI, UniProt]. This activity is essential for the proper folding and stability of various secreted and membrane-bound proteins, particularly those involved in the assembly of the extracellular matrix (ECM), such as laminin [Wikipedia, UniProt]. In many aggressive human cancers, including pancreatic, breast, and lung carcinomas, QSOX1 is significantly overexpressed and promotes tumor cell migration, invasion, and metastasis by modulating ECM architecture and activating matrix metalloproteinases [MDPI, PMC, PubMed: 31575656]. Consequently, QSOX1 has emerged as a promising therapeutic target and a potential diagnostic biomarker for early cancer detection [Patsnap, ClinicalTrials.gov]. Experimental inhibitors, such as the small molecule SBI-183 and the monoclonal antibody MAb492.1, have demonstrated the ability to suppress tumor growth and metastasis in preclinical models by disrupting the enzyme's catalytic function [PubMed: 31575656, Innoget]. Additionally, QSOX1 expression has been linked to drug resistance and sensitivity, such as promoting sorafenib-induced ferroptosis in hepatocellular carcinoma [PMC: 10.1038/s41419-021-03812-w].
Inhibition of enzymatic sulfhydryl oxidase activity through catalytic site binding or steric hindrance, leading to impaired disulfide bond formation and disrupted extracellular matrix assembly [PubMed: 31575656, Innoget, Patsnap].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Quiescin sulfhydryl oxidase 1 (QSOX1) (QSOX1).